logo
Salmon Recall Update as FDA Sets Most Serious Risk Level

Salmon Recall Update as FDA Sets Most Serious Risk Level

Newsweek17 hours ago

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
The Food and Drug Administration (FDA) has announced its classification of Santa Monica Seafood Company's recall of its "Atlantic Salmon Portions with Seafood Stuffing" product as the highest risk category.
The FDA classified the recall as a Class I, due to the fact the product contained an undeclared allergen—soy.
Newsweek has contacted Santa Monica Seafood Company outside of regular hours via email for comment.
Why It Matters
Soy is one of the nine major allergens alongside tree nuts, peanuts, wheat, sesame, milk, eggs, fish and crustacean shellfish. While it is not the most common allergy in the country, almost 2 million Americans cannot eat soy, according to a report by Food Allergy Research and Education (FARE).
For Americans with food allergies, products that do not have clear allergen information pose high and even life-threatening risks. Allergic reactions can vary from milder symptoms to severe skin reactions, sneezing, vomiting or life-threatening airway swelling.
A photo of the affected product in the Santa Monica Seafood Company.
A photo of the affected product in the Santa Monica Seafood Company.
FDA
What To Know
Santa Monica Seafood recalled its "Atlantic Salmon Portions with Seafood Stuffing" on May 24, and the FDA proceeded to classify the recall on June 12.
A Class I classification indicates it is a situation in which "there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death."
The affected product was sold in 16 oz packages, with a lot number of 197940521, a use or freeze by date of June 2, 2025, and a UPC 4061459716313.
In total, 150 cases of the product were distributed to Aldi stores in California, Nevada, and Arizona.
The company identified the issue during an inspection of label proofs from a completed production batch, when it was found that the allergen, soy, was not listed in the ingredients.
"This labeling error means that individuals with a soy allergy may unknowingly consume the product," the company said in its announcement.
No allergic reactions connected to this recall had been reported as of May 24, and the FDA did not disclose if any had been reported in its classification update.
What People Are Saying
James R. Baker Jr., a professor of biologic nanotechnology and internal medicine at the University of Michigan Medical School, told Newsweek: "A person with soy allergy would react immediately after they ate a contaminated food. In that it could be within actually a few minutes of eating, they can experience reactions such as a skin, rash or swelling, trouble breathing, and that could evolve into dangerously low blood pressure. There may be a little warning of this type of allergic reaction however, they may notice some tingling in their lips or tongue before the more serious elements of the reaction occur."
What Happens Next
Consumers with soy allergies who purchased the recalled salmon are urged not to eat it and to return it to the place of purchase for a full refund. For questions, consumers may contact Santa Monica Seafood at 1-800-969-8862, Monday through Friday, from 8 a.m. to 5 p.m. PST.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Capricor treatment of Becker muscular dystrophy granted orphan designation
Capricor treatment of Becker muscular dystrophy granted orphan designation

Business Insider

time2 hours ago

  • Business Insider

Capricor treatment of Becker muscular dystrophy granted orphan designation

The FDA granted orphan designation to a treatment of Becker muscular dystrophy being developed by Capricor, according to a post to the agency's website. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Insmed Inc (INSM) Soars 30% on Impressive Study
Insmed Inc (INSM) Soars 30% on Impressive Study

Yahoo

time3 hours ago

  • Yahoo

Insmed Inc (INSM) Soars 30% on Impressive Study

We recently published a list of . In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands against other top-performing companies on Tuesday. Insmed Inc. soared by 28.65 percent on Tuesday to close at $90.93 apiece following positive results from the phase 2 trial of its pulmonary arterial hypertension (PAH) treatment, treprostinil palmitil inhalation powder (TPIP). Insmed Incorporated (NASDAQ:INSM) jumped as high as 30 percent at intraday trading following the announcement. According to the company, the phase 2 trial achieved its primary and secondary goals for the treatment of reducing blood pressure in the lungs and improving exercise capacity in patients. Following the results, Insmed Incorporated (NASDAQ:INSM) said it would engage with the Food and Drug Administration (FDA) regarding the phase 3 trial design. The company said it plans to initiate a Phase 3 trial in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) before the end of the year, to be followed by a Phase 3 trial in patients in early 2026. A biopharmaceutical research team taking notes in front of a laboratory's microscope. 'These unprecedented Phase 2b results unequivocally demonstrate TPIP's potential to be a highly effective and well-tolerated once-daily prostanoid therapy for the treatment of PAH across disease severities and background treatment regimens. We look forward to expanding upon these results in the upcoming Phase 3 program,' the company said. Overall, INSM ranks 1st on our list of top-performing companies on Tuesday. While we acknowledge the potential of INSM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

KalVista says FDA will not meet PDUFA goal date for Sebetralstat NDA
KalVista says FDA will not meet PDUFA goal date for Sebetralstat NDA

Business Insider

time4 hours ago

  • Business Insider

KalVista says FDA will not meet PDUFA goal date for Sebetralstat NDA

KalVista (KALV) Pharmaceuticals nnounced that the U.S. Food and Drug Administration has notified the company that it will not meet the PDUFA goal date for the New Drug Application for sebetralstat, the company's investigational oral on-demand treatment for hereditary angioedema. The FDA notified the company on June 13, 2025, that the previously disclosed June 17, 2025 PDUFA goal date will not be met due to heavy workload and limited resources. The FDA indicated that it expects to deliver a decision within approximately four weeks. The FDA has not requested additional data or studies and has not raised any concerns regarding the safety, efficacy or approvability of sebetralstat. KalVista has addressed all prior information requests in a timely manner, and the company believes the only remaining item under FDA review is the finalization of the labelling. 'We are disappointed by this delay, most importantly because we know how much people living with HAE are looking forward to an oral on-demand option to treat their HAE attacks,' said Ben Palleiko, CEO of KalVista. 'At the same time, we remain confident in the near-term approval of sebetralstat. We are continuing to work closely with the FDA to support the completion of their review. Our commitment to bringing this important therapy to people living with HAE remains unwavering.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store